GlassScriptPhysician profile
Alice V Davis
NPI 1598741621
$1,253.43
in general payments reported to CMS, 2019-2025
23 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $276 · 2022: $137 · 2023: $191 · 2024: $270 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $840.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $269.37 | 2021-2025 | Wegovy |
| Abbvie INC. | $240.21 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $118.08 | 2023-2025 | Austedo Xr, Austedo |
| Pfizer INC. | $116.90 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.29 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $65.04 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $54.86 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $44.12 | 2022 | |
| Lundbeck LLC | $33.49 | 2024-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $33.23 | 2023-2025 | Breztri |
| Amarin Pharma, INC. | $31.34 | 2021 | |
| Astellas Pharma US INC | $19.98 | 2023 | Veozah |
| Nestle Healthcare Nutrition INC. | $16.44 | 2021 | |
| Organon LLC | $15.91 | 2023 | Nexplanon |
| Axsome Therapeutics, INC. | $15.88 | 2023 | Auvelity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $15.28 | 2024 | Proclaim |
| Radius Health, INC. | $15.06 | 2021 | |
| Sumitomo Pharma America, INC. | $14.24 | 2024 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $14.16 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.63 | 2025 | |
| Lilly USA, LLC | $13.42 | 2024 | Jardiance |
| Amgen INC. | $12.50 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alice Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.